Table 2. Characterization of patients with end-stage heart failure.
Heart failure patients (n = 18) | |
---|---|
Age (years) | 48.9 ± 2.4 |
Gender | n = 14 males, n = 4 females |
NYHA class | n = 8 NYHA III, n = 10 NYHA IV |
Pro-BNP (pmol/L) | 417.0 ± 85.0 |
BMI (kg/m2) | 26.0 ± 0.7 |
LVEF (%) | 19.2 ± 1.6 |
LVEDV (ml) | 279.0 ± 23.2 |
LVESV (ml) | 227.9 ± 21.7 |
SV (ml) | 51.1 ± 3.6 |
WMSI | 2.42 ± 0.04 |
IVSd (cm) | 0.81 ± 0.05 |
LVPWd (cm) | 0.71 ± 0.02 |
LVIDd (cm) | 7.41 ± 0.22 |
Clinical and echocardiography data (mean±SEM) of patients with end-stage heart failure with reduced ejection fraction (HFrEF). Non-diseased hearts considered for transplantation but deemed unsuitable were used as control samples (age 46.9 ± 7.5 years, n = 4 males and n = 3 females). NYHA, New York Heart Association; BMI, body mass index; BNP, brain natriuretic peptide; LVEF, left ventricular ejection fraction; WMSI, wall motion score index [8]; LVEDV, LV end diastolic volume; LVESV, LV end systolic volume; SV, stroke volume; IVSd, interventricular septal diameter in diastole; LVIDd, LV internal diameter in diastole; LVPWd, LV posterior wall thickness in diastole.